Journal: PLoS Neglected Tropical Diseases

Article Title: Human Leukocytes Kill Brugia malayi Microfilariae Independently of DNA-Based Extracellular Trap Release

doi: 10.1371/journal.pntd.0005279

Figure Lengend Snippet: A: The percentage of Mf that had at least one PMN adhered to their surface or indirectly fastened by extracellular DNA at 24 hours post-experimental set up (n = 3). Orange and red bars represent 5% autologous serum and 25% autologous serum treated wells respectively. The autologous serum was either untreated (no peptide control), treated with 100μM inactive compstatin analogue (control peptide) or treated with 100μM active compstatin. Error bars represent standard error of the mean. B: The percentage of Mf that survived 5 days in the presence of both PMNs and PBMCs after treatment of serum with control peptide or compstatin (n = 3). C: PMNs were incubated with blocking antibodies for 2 hours prior to incubation with Mf for 5 days. PMN-mediated killing occurred to the same extent in control (no antibody) wells and those treated with anti-ICAM-1 and anti-Cd11b (p = <0.0001). No significant differences were observed between PMN incubated with Mf with or without the anti-ICAM-1 or anti-Cd11b (n = 3).

Article Snippet: For the compstatin inhibition studies, autologous serum was pretreated with either 100μM compstatin (Tocris Bioscience, Avonmouth, Bristol, U.K.) or 100μM compstatin control peptide (Tocris Bioscience, Avonmouth, Bristol, U.K.) for 30 min at 37°C.

Techniques: Control, Incubation, Blocking Assay

Journal: Pharmacology Research & Perspectives

Article Title: An integrin antagonist ( MK ‐0429) decreases proteinuria and renal fibrosis in the ZSF 1 rat diabetic nephropathy model

doi: 10.1002/prp2.354

Figure Lengend Snippet: (A) The expression of various integrins in primary human kidney cells. Following immunoprecipitation with an anti‐ α v antibody, the α v β 1, α v β 3, α v β 5, and α v β 6 heterodimers were detected by automated western analysis using antibodies that recognize the individual β ‐subunit. GAPDH level in total cell lysate was used as loading control. Human primary kidney fibroblasts ( HPKF ), human primary renal proximal tubule epithelial cells ( RPTEC ), and normal human mesangial cells ( NHMC ). IP , immunoprecipitation; IB , immunoblotting. (B) MK ‐0429 inhibits podocyte motility in Oris cell migration assay. Cells were exposed to puromycin ( PAN , 15 μ g/mL) for 24 h in the presence or absence of MK ‐0429 at different concentrations (ranging from 0.01 nmol/L to 10 μ mol/L, n = 8 for each concentration). ** P < 0.01, one‐way ANOVA . (C) MK ‐0429 suppresses the expression of fibrosis marker genes in HPKF s under basal condition or upon TGF ‐ β stimulation ( n = 8 for each group). PAI ‐1, plasminogen activator inhibitor‐1; α SMA , α ‐smooth muscle actin; Col IA 1, Collagen type I alpha‐1 chain; CTGF , connective tissue growth factor.

Article Snippet: Human recombinant α 1 β 1, α 2 β 1, α 3 β 1, α 4 β 1, α 6 β 1, α 9 β 1, α 10 β 1, α 11 β 1, and α IIb β 3 integrins from R&D Systems were reconstituted in assay buffer and Sypro orange (Sigma‐Aldrich, St. Louis, MO).

Techniques: Expressing, Immunoprecipitation, Western Blot, Control, Cell Migration Assay, Concentration Assay, Marker

Journal: Pharmacology Research & Perspectives

Article Title: An integrin antagonist ( MK ‐0429) decreases proteinuria and renal fibrosis in the ZSF 1 rat diabetic nephropathy model

doi: 10.1002/prp2.354

Figure Lengend Snippet: In vitro selectivity of MK‐0429 against various integrin subtypes

Article Snippet: Human recombinant α 1 β 1, α 2 β 1, α 3 β 1, α 4 β 1, α 6 β 1, α 9 β 1, α 10 β 1, α 11 β 1, and α IIb β 3 integrins from R&D Systems were reconstituted in assay buffer and Sypro orange (Sigma‐Aldrich, St. Louis, MO).

Techniques: In Vitro, Inhibition, Binding Assay